Effects of allisartan, a new at 1 receptor blocker, on blood pressure and end-organ damage in hypertensive animals

Acta Pharmacologica Sinica

Volumn 30, Issue 3, 2009, Pages 307-313

  Wu, Ming Yue ^a   Ma, Xiu Juan ^a   Yang, Chu ^a   Tao, Xia ^a   Liu, Ai Jun ^a   Su, Ding Feng ^a   Liu, Jian Guo ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Allisartan; Angiotensin II type 1; Arterial baroreflex; Blood pressure; End organ damage; Hypertension

Indexed keywords

ALLISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; LOSARTAN; UNCLASSIFIED DRUG; ANGIOTENSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOG; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; FEMALE; HYPERTENSION; HYPOTENSION; LONG TERM CARE; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRESSORECEPTOR REFLEX; RAT; RENOVASCULAR HYPERTENSION; SINGLE DRUG DOSE; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; BLOOD PRESSURE; DRUG EFFECT; HEART RATE; HUMAN; KIDNEY; MOUSE; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; DOGS; FEMALE; HEART RATE; HUMANS; HYPERTENSION, RENOVASCULAR; KIDNEY; LOSARTAN; MALE; MICE; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY;

EID: 64849102717     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.11     Document Type: Article

References (35)

1. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-19.
2. Hirose H, Saito I. Trends in blood pressure control in hypertensive patients with diabetes mellitus in Japan. Hypertens Res 2003; 26: 717-22.
3. DzauVJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-52.
4. Zhang C, Hein TW, Wang W, Kuo L. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microva-scular function. Circ Res 2003; 92: 322-9.
5. Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6: 28-32.
6. Rakugi H, Ogihara T. The usefulness of a new class antihy-pertensive drug, angiotensin II receptor antagonist, for essential hypertension. Nippon Rinsho 1999; 57: 1141-7.
7. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 255:211-7.
8. Munafo A, Christin Y, Nussberger J, Shum LY, Borland RM, Lee RJ, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992; 51: 513-21.
9. Stearns R?, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. DrugMetab Dispos 1995; 23: 207-15.
10. Shen FM, Xie HH, Ling G, Xu LP, Su DF. Synergistic effects of atenolol and amlodipine for lowering and stabilizing blood pressure in 2K1C renovascular hypertensive rats. Acta Pharmacol Sin 2005; 26: 1303-8.
11. PangH, WenYY, Ma N, WangYT, ShiL. Protective role of a novel erythrocyte-derived depressing factor on blood vessels of renovascular hypertensive rats. Clin Exp Pharmacol Physiol 2007; 34: 393-8.
12. Hashimoto Y, Ohashi R, Minami K, Narita H. Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension. Jpn J Pharmacol 1999; 81: 63-72.
13. Liu AJ, Ma XJ, Shen FM, Liu JG, Chen H, Su DF. Arterial barore-flex: a novel target for preventing stroke in rat hypertension. Stroke 2007; 38: 1916-23.
14. Zhang W, Liu AJ, Yi-MingW, Liu JG, Shen FM, Su DF. Pressor and non-pressor effects of sodium loading on stroke in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2008; 35: 83-8.
15. Hayakawa H, Raij L. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension 1997; 29: 235-41.
16. Zhang HG, Li XH, Zhou JZ, Liu Y, Jia Y, Yuan ZB, et al. G(alphaq)-protein carboxyl terminus imitation polypeptide GCIP-27 attenuates cardiac hypertrophy in vitro and in vivo. Clin Exp Pharmacol Physiol 2007; 34: 1276-81.
17. Miao CY, XieHH, WangJJ, SuDF. Candesartan inhibits sinoao-rtic denervation-induced cardiovascular hypertrophy in rats. Acta Pharmacol Sin 2002; 23: 713-20.
18. Shen FM, Wang J, Ni CR, Yu JG, Wang WZ, Su DF. Ketanserin-induced baroreflex enhancement in spontaneously hypertensive rats depends on central 5-HT(2A) receptors. Clin Exp Pharmacol Physiol 2007; 34: 702-7.
19. Smyth HS, Sleight P, Pickering GW. Reflex regulation of arterial pressure during sleep in man: a quantitative method of assessing baroreflex sensitivity. Circ Res 1969; 24: 109-21.
20. Luepker RV, Arnett DK, Jacobs DRJr, Duval SJ, Folsom AR, Armstrong C, et al. Trends in blood pressure, hypertension control, and stroke mortality: the Minnesota Heart Survey. Am J Med2006; 119:42-9.
21. BansalD, Chahoud G, Smith ES, MehtaJL. Prevention of heart failure. Curr Opin Cardiol 2006; 21: 510-6.
22. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens 2008; 26: 1477-86.
23. Zoungas S, Asmar RP. Arterial stiffness and cardiovascular outcome. Clin Exp Pharmacol Physiol 2007; 34: 647-51.
24. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356:1955-64.
25. Xie HH, Miao CY, Liu JG, Su DF. Importance of blood pressure variability in organ protection in spontaneously hypertensive rats treated with combination of nitrendipine and atenolol. Acta Pharmacol Sin 2002; 23: 1199-204.
26. Su DF, Miao CY. Blood pressure variability and organ damage. Clin Exp Pharmacol Physiol 2001; 28: 709-15.
27. Shan ZZ, Dai SM, Su DF. Relationship between baroreceptor reflex function and end-organ damage in spontaneously hypertens ive rats. AmJ Physiol 1999; 277: H1200-6.
28. Su DF, Maio CY. Reduction of blood pressure variability: a new strategy for the treatment of hypertension. Trends Pharmacol Sci 2005; 26: 388-90.
29. Trippodo NC, Frohlich ED. Similarities of genetic (spontaneous) hypertension: man and rat. Circ Res 1981; 48: 309-19.
30. Zhou X, Frohlich ED. Analogy of cardiac and renal complications in essential hypertension and aged SHR or L-NAME/SHR. Med Chem2007;3:61-5.
31. Shiono K, Sokabe H. Renin-angiotensin system in spontaneously hypertensive rats. AmJ Physiol 1976; 231: 1295-9.
32. Wang X, Aukland K, Iversen BM. Autoregulation of total and zonal glomerular filtration rate in spontaneously hypertensive rats during antihypertensive therapy. J Cardiovasc Pharmacol 1996; 28: 833-41.
33. Iversen BM, Sekse I, OfstadJ. Resetting of renal blood flow autoregulation in spontaneously hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 1987; 252: F480-F486.
34. Martinez-Maldonado M. Pathophysiology of renovascular hypertension. Hypertension 1991; 17: 707-19.
35. Navar LG, Zou L, Von Thun A, Tarng Wang C, Imig JD, Mitchell KD. Unraveling the mystery of Goldblatt hypertension. News Physiol Sci 1998; 13: 170-6.